CVS plans to separate its pharmacy and health-benefits businesses by 2028, while Texas governor-elect Gina Hinojosa pledges to push for Medicaid expansion.
CVS Health plans to split into two publicly traded companies by the first half of 2028, separating its roughly 9,000 retail pharmacies from its insurance and health-services businesses. The Nov. 4 announcement puts a central question before patients and employers: whether reorganizing a company that spans prescriptions, insurance and care will change what medicines are covered or what patients pay.
One company would operate CVS Pharmacy locations. The other, also called CVS Health, would include Aetna, pharmacy-benefit manager Caremark, primary-care operations and related businesses. CVS said the separation is intended to be tax-free for existing shareholders, who would receive ownership in both companies. It announced no pharmacy closures as part of the plan.
Investors reacted negatively: CVS shares fell 10% after the announcement, CNBC reported. But the market move does not establish what the split will mean for patients. CVS has not detailed changes to benefit designs, prescription prices or how its pharmacy and insurance operations will coordinate after separation.
Novo Nordisk CEO Mike Doustdar said the breakup has no material impact on the drugmaker beyond requiring separate negotiations with the successor companies over formulary placement. Formularies determine which medicines a health plan covers and on what terms, so negotiations can influence patient access. The available reports provide no details on how either future company will set coverage or pharmacy terms.
Novo is reporting stronger sales as it raises its full-year outlook. The company increased its 2026 forecast for constant-currency adjusted sales and operating-profit growth to minus 2% to plus 2%, from minus 6% to zero. Third-quarter net sales reached 79.2 billion Danish kroner, compared with 74.98 billion a year earlier. The improved outlook followed strong uptake of its Wegovy pill.
Those figures document commercial growth, not what patients will pay for the medicine or whether their plans will cover it. CVS’s split may mean two negotiating counterparties instead of one, but Doustdar described the impact on Novo as limited to separate formulary discussions. No patient-level changes have been announced.
Doustdar also said Novo remains interested in acquisitions that could “close some of the gaps” in its pipeline, while taking a disciplined approach to deals, Fierce Biotech reported. The source material identifies no potential targets or specific implications for patients.
In Texas, governor-elect Gina Hinojosa said she would urge the Legislature to expand Medicaid, prioritizing health-care access for every child. She said the federal government would cover most of the cost.
The proposal would bring questions about both coverage and the state budget. The available reporting does not estimate how many Texans might gain insurance, quantify the state’s costs or provide eligibility rules and a timeline. Those details will be central to lawmakers’ assessment of the proposal and its potential reach.
The developments show two ways business and policy decisions can shape access: negotiations between drugmakers and health-benefit companies, and state choices about public coverage. Neither CVS’s announced reorganization nor Hinojosa’s stated goal specifies a measurable change in care yet. The outcomes will depend on the contracts, coverage terms and legislation that follow.
Susan Carter serves as a Senior Correspondent for Just Right News, where she leads the network’s comprehensive coverage of Health, Medicine, and Public Policy. With a career dedicated to dissecting the complexities of the American healthcare system, Susan brings a principled perspective to the most pressing debates of the day. Her reporting is characterized by a commitment to individual liberty, fiscal responsibility, and a healthy skepticism of government overreach, making her a vital voice for audiences seeking clarity in an increasingly regulated landscape.
Raised in Minneapolis, Minnesota, Susan’s professional outlook is deeply informed by the values of the American heartland. Growing up in the Twin Cities, she witnessed firsthand the importance of community-driven solutions and the resilience of the individual. This Midwestern foundation instilled in her a firm belief that the best answers to public policy challenges often come from local innovation and personal responsibility rather than top-down federal mandates. Her background allows her to translate complex legislative jargon into stories that resonate with families who value common sense and local autonomy.
Now based in Baltimore, Maryland, Susan operates from a unique vantage point at the intersection of medical innovation and urban policy. Living and working in a city renowned for its world-class medical institutions and significant public health challenges, she has a front-row seat to the realities of the modern healthcare landscape. Her proximity to these hubs of research and policy allows her to scrutinize how government intervention affects the quality of care and the freedom of medical professionals. In Baltimore, she sees the tangible results of policy decisions, using the city as a lens through which to examine the broader national health debate and the impact of federal spending on local communities.
As the lead for the acclaimed feature series “The Cost of Care,” Susan dives deep into the economic realities facing patients and providers alike. Her work focuses on the necessity of price transparency, the benefits of market competition, and the preservation of the sacred doctor-patient relationship. She is a staunch advocate for the idea that a well-informed public is the best defense against bureaucratic inefficiency. Through this series, she has exposed the hidden drivers of rising medical expenses, always seeking to empower the individual consumer over the massive institution.
Susan’s reporting on public policy is characterized by a commitment to rigorous inquiry and a focus on constitutional limits. Whether she is analyzing new pharmaceutical regulations, investigating the impact of federal health mandates, or exploring the future of medical technology, her goal remains the same: to provide Just Right News audiences with the facts they need to navigate a complex world. By blending her Midwestern sensibilities with the insights gained from her base in Maryland, Susan Carter has become a trusted authority for those who believe that personal freedom and public health are inextricably linked. Her work continues to challenge the status quo, advocating for a system that respects the taxpayer and prioritizes the patient.